Background: The detection of mutations associated with drug resistance in HIV type-1 might be increased by applying minority species assays capable of identifying low frequency mutations in comparison with the use of population sequencing alone. Because minority species assays are mutation-specific, the benefit of this approach differs depending on the mutation being detected. Methods: We performed a systematic review of published data reporting detection of genotypic drug resistance using allele-specific (AS)-PCR minority assays and by standard DNA sequencing in drug-naive populations. We calculated the fold increase of mutation detection for each study and pooled these via meta-analysis, displaying results using Forest plots. Results: Our studies revealed an increase in detection of 1.9-fold (95% confidence interval [CI] 1.3-2.7; P<0.0005) for K103N, 4.4-fold (95% CI 1.2-16.6; P=0.026) for Y181C, 4.8-fold (95% CI 1.5-15.1; P=0.008) for L90M and 8.7-fold (95% CI 4.0-18.6; P<0.0005) for M184V. We found no relationship between AS-PCR assay sensitivity and frequency of additional mutation detection. Conclusions: Additional detection of drug resistance mutations using AS-PCR minority mutation assays vary significantly depending on the mutation examined; however, the most marked increase in detection of resistance mutations was observed for M184V, a mutation seldom detected by standard techniques in drug-naive patients. We suggest that the presence of drug resistance mutations can be more accurately estimated using a combination of AS-PCR and standard genotyping.
Antiretroviral therapy (ART) has significantly reduced the burden of morbidity and mortality in HIV type-1 (HIV-1)-infected individuals [1] ; however, some patients develop virus that is resistant to the drugs used and such drug-resistant virus can be further transmitted. Genotypic resistance testing is recommended following diagnosis in order to identify transmitted drug resistance mutations in the infecting strain [2] . Some transmitted drug resistance mutations are long-lived, whereas others are thought to disappear rapidly, probably because of fitness costs [3] .
Minority HIV-1 variants (<20% of the plasma population) are undetectable in standard genotyping assays, which use population sequencing [4] . A number of recently published studies have used more sensitive assays that are capable of detecting minority drug-resistant populations. Traditional approaches have included PCR-cloning techniques to study genome populations, but these tend to be labourious and lack adequate sensitivity. Recently, more sophisticated laboratory techniques have included ultra-deep sequencing [5, 6] , parallel allele-specific (AS) sequencing [7] , oligonucleotide ligation [8] and AS-PCR. Of these, AS-PCR has been most widely applied. This method employs specific oligonucleotide PCR primers that bind only to mutant alleles, thereby limiting amplification to molecules carrying that particular allele, with amplification being monitored by real-time PCR [9] . Such assays can detect minority mutant populations with a limit of sensitivity reportedly as low as 1:100,000, although the minimum level at which these populations will adversely affect subsequent ART remains to be ascertained. One potential advantage of such an assay is to better estimate the rate of transmitted resistance, as some variants might Introduction revert to wild type over time, and therefore be present only at low proportions of the overall population.
We have undertaken a meta-analysis of studies using AS-PCR to detect minority HIV-1 drug resistance, in order to identify the extent to which AS-PCR offers additional sensitivity over standard genotyping in ART-naive populations for commonly observed drug resistance mutations. We present meta-analyses of four drug resistance mutations, and demonstrate that the improved detection of drug resistance mutations using minority species assays with genotyping, compared with standard genotyping alone, is mutation specific.
Methods

Search strategy
The ), and to articles for which all of the string words appeared anywhere in the title or abstract. The two search strings were 'minority HIV drug resistance' and 'allele-specific HIV drug resistance'. For conference abstracts from CROI and IHDRW, two search strings were used. These were limited to the appearance in the abstract and title of the words 'minority' or 'allelespecific'. In addition to the formal search strings, further searches of the references appearing in articles matching the inclusion criteria were performed. When necessary, study authors were contacted for further data, or to confirm technical questions arising from our analyses.
Inclusion criteria for eligible studies
Any study was considered if it described the detection of minority populations of drug resistance mutations using AS real-time PCR techniques in addition to the use of standard genotyping by population sequencing studies. Specific mutations included in this meta-analysis included three reverse transcriptase mutations, K103N, Y181C and M184V, and the major protease inhibitor mutation, L90M. HIV-1 infections caused by any group M subtype were included in our dataset. Articles were recorded for further analysis if they included ART-naive populations. We have included only articles written in English in our analyses.
Exclusion criteria
Studies that were excluded from our review were those that appeared to duplicate data (for example, both in conference proceedings and full papers), case reports, studies that used minority species assays other than AS-PCR, studies without a detailed patient breakdown and research using AS-PCR to study the reversion of predominant drug resistant quasispecies. Studies that exclusively used ART-experienced patients were also excluded. Articles were independently assessed for eligibility by two investigators.
Statistical analyses
We aimed to assess the degree to which AS-PCR detection of specific mutants increased the estimates of drug resistance over population sequencing by comparing the same population tested using the two types of drug resistance assays, that is, direct DNA sequencing and minority-specific AS-PCR assays, for four drug resistance mutations. When comparing AS-PCR versus standard methods, McNemar's test for paired data was used. Some data manipulation was required: where zero cells were encountered in the 2×2 table because a standard test detected no mutations or both tests detected an equal number of cases, a continuity correction was applied, adding 0.5 to each group in the former case or adding 0.5 to off-diagonal cells in the latter. This means that results were biased slightly towards the null (that is, less benefit of AS-PCR) in cases where a standard test detected no mutations or that the standard error was underestimated when both tests detected an equal number of cases. Furthermore, studies that did not detect any mutations with either test were included by adding 0.25 to each cell. This adjustment allowed studies for which there was a large amount of uncertainty to be included in the analyses. Arguably, such studies contained no data, but we propose that they were informative by indicating that AS-PCR was not providing an increase in detections; hence, the pooled relative risk was moved marginally towards the null.
The log relative risk and standard errors were pooled for each genotype using the random effects method proposed by DerSimonian and Laird [10] and the fixed-effect method. Heterogeneity was assessed via the I-squared statistic for heterogeneity [11] and its P-value. All analyses were performed using Stata version 10.1 (StataCorp, College Station, TX, USA) and meta-analysis and forest plots using fixed-and random-effects meta-analysis. Meta-regression was used to examine the relationship between AS-PCR assay sensitivity and additional transmitted drug resistance detection. Individual assay sensitivities are presented in Table 1 .
Results
Of the 83 abstracts that were identified through the search strategy, 46 (55.4%) articles were found from searches of the PubMed database. A total of 24 (28.9%) articles were identified from the conference proceedings of CROI, and 13 (15.6%) from IHDRW. Of these, 60 (72.2%) were excluded after the primary screen and the remaining 23 were reviewed. Full articles or posters were obtained, where possible. In cases where this was not possible or where abstracts were unclear, authors were contacted directly by e-mail to address specific questions. Common reasons for exclusion included studies that used ART-experienced patients or studies that used minority detection assays other than AS-PCR. A total of 13 (16%) articles were reviewed by two investigators and were included in the meta-analyses. The outcome of the search strategies is summarized in Figure 1 .
Data from 987 patients were analysed. The characteristics of each study are described in Table 1 . They included data from the US and Canada (n=480), Switzerland and Germany (n=179), the UK (n=165), South Africa (n=108), Argentina (n=35) and Uganda (n=20).
The patient tests studied were baseline assessments from prospective treatment cohorts that included prevention of mother-to-child transmission prophylaxis cohorts, surveillance studies in undiagnosed patients or primary HIV-1 infection cohorts. All patients included in the analyses were reported to be ART-naive. Each study was analysed to exclude any patients who were pre-selected, for instance, when used as controls, or who were ART-experienced.
Separate analyses were performed for four HIV-1 drug resistance mutations. The number of mutations detected solely by standard genotyping with population DNA sequencing was compared with the number identified by standard genotyping and AS-PCR combined. Forest plots for the four mutation analyses are shown in Figure 2 .
For the nucleoside reverse transcriptase inhibitor mutation M184V, data were analysed from nine studies. 
K103N
Johnson et al. [18] Metzner et al. [26] Metzner et al. [19] Johnson et al. [21] Pillay et al. [20] Buckton et al. [15] Coovadia et al. [25] Hauser et al. [24] Metzner et al. [28] Metzner et al. [22] Paredes et al. [12] Toni et al. [23] Vignoles et al. [27] Overall (P<0.0005)
M184V
Metzner et al. [22] Metzner et al. [28] Johnson et al. [21] Buckton et al. [15] Metzner et al. [19] Metzner et al. [26] Toni et al. [23] Vignoles et al. [27] Overall (P<0.0005) 
Y181C
Johnson et al. [18] Johnson et al. [21] Buckton et al. [15] Hauser et al. [24] Metzner et al. [26] Paredes et al. [12] Overall (P=0.0265)
L90M
Metzner et al. [28] Metzner et al. [19] Johnson et al. used to investigate the relationship between increasing mutation detection and assay sensitivity. P-values for each mutation were P=0.617, P=0.633 and P=0.594 for M184V, K103N and Y181C, respectively. L90M had too few studies to perform this test; therefore, there were no significant relationships between the application of more sensitive AS-PCR tests and increased frequency of minority drug resistance detection.
Discussion
This study reviews data derived from mutation-specific minority species assays, using AS-PCR, to investigate the rate of prevalence of drug resistance in treatmentnaive patients. Sufficient published data were available to perform meta-analyses of four key HIV-1 drug resistance mutations, representing three classes of ART drugs. The increase in drug resistance detected using mutation-specific AS-PCR minority assays together with population sequencing, as compared with standard genotyping alone, was determined. The increased detection of resistance mutations by adding minority AS-PCR assays varied markedly depending on which mutation was being examined. The greatest additional increase across all the studies was for the incorporation of the M184V mutation assay. An 8.7-fold (95% CI 4.0-18.6; P≤0.0005) expected increase in detection for this mutation was found when using AS-PCR. By contrast, additional detections were least likely for the K103N mutation, which showed a 1.9-fold (95% CI 1.3-2.7; P≤0.0005) increase in its detection when using AS-PCR assays compared with standard genotyping alone. Analysis of the protease inhibitor mutation, L90M, and the non-nucleoside reverse transcriptase inhibitor mutation, Y181C, showed an increase of 4.8-fold (95% CI 1.2-16.6; P=0.008) and 4.4-fold (95% CI 1.2-16.6; P=0.026), respectively. For both assays, relatively few studies have examined these mutations. The CIs are consequently wider and the outcomes less certain, but the increase in detection is still significant for both analyses. In the case of the Y181C mutation there was variability in the estimated increase in detection, ranging between a 0-and 65-fold increase in Y181C detection when using AS-PCR compared with standard genotyping. If these analyses were repeated, excluding the outlying data point from the large increase in detections by Paredes et al. [12] , the expected increase in detection was more modest and changed to 2.2-fold (95% CI 1.0-5.3), with marginal statistical significance (P=0.08; AJB et al., data not shown). A further source of bias in the data used for this study is the unusually high prevalence of wild-type strains, as determined by standard genotyping. This might have arisen because the data used often excluded patients with drug resistance mutations because it was not always possible to determine that they were ARTnaive. Finally, drug resistance mutation detection is sometimes more likely in recent infections, although studies have shown that some mutations can be very long-lived [13] . An unequal representation of recent infections among the study cohorts could bias the prevalence reported in the source studies. It was not possible to determine the proportion of recent infections in this data set.
Why is there such a marked difference in additional detection of drug resistance mutations using AS-PCR for different mutations? This effect might be best explained by the fitness cost associated with each mutation. It is well-known that the replicative capacity of drug resistant viruses can be lower when compared with wildtype parental HIV-1 strains. One study examined the fitness difference of mutant-containing viruses relative to a wild-type strain and showed decreasing fitness for viruses containing Y181C, K103N and M184V of 1.4-fold, 6.2-fold and 14-fold reductions in replicative capacity, respectively [14] . This trend is in line with the finding of the additional detections using more sensitive minority species assays to date. Thus, AS-PCR might be of most use for drug resistance mutations with a high fitness cost, as they are infrequently detected in treatment-naive patients using standard assays, but are still clinically relevant because of viral DNA archiving in the lymphocyte population. The fold increase differences determined in this study for each mutation can in part be explained by their relative frequency in drug resistance studies using standard genotyping methods. Some mutations are rarely observed in baseline studies; for example, only 1/165 patients had the M184V mutation in a recent UK study [15] . Therefore, even modest increases in detection, using AS-PCR, will significantly change the fold increase of detection in this type of study. By extension, it is also likely that strains carrying drug resistance mutations that have a lower fitness cost are less frequently undetected in standard genotyping assays. This analysis included a broad range of HIV-1 subtypes; however, AS-PCR assays are highly sequencespecific, and separate assays might have to be developed for each subtype. A limitation of all minority species assays, including AS-PCR, is that they are prone to detect background nucleotide polymorphisms, generated by HIV-1 reverse transcriptase during genome replication. The increase in drug resistance using AS-PCR assays might also be explained by detection of naturally occurring sequence polymorphism, that is, identifying low level de novo mutations generated at resistanceassociated codons. Estimates suggest that every possible HIV-1 variant can exist at a level of 0.01% [16] . This has been indicated as a limiting factor for the degree of sensitivity of ultra-deep sequencing assays. These limitations should also apply to studies using AS-PCR; however, a single cutoff cannot be assigned because it is dependent on several factors including specimen viral load and the relative associated fitness cost of certain mutations. Therefore, studies using assays with a discriminative end point sensitivity in the range of 0.01%, as determined using clonal sequence mixtures generated in the laboratory, could detect naturally occurring background polymorphism, which does not represent instances of drug resistance. This effect will be exacerbated by the inherent error rate of reverse transcriptase PCR used in all laboratory procedures for HIV-1 gene amplification [17] . It is interesting to note that studies using AS-PCR methods with end point sensitivities <0.01% did not detect minority drug resistance in all their study samples, supporting the theory that there is a dynamic range at which de novo polymorphism becomes more apparent. Nonetheless, future studies should be mindful of these sources of error when assigning AS-PCR discriminative sensitivities. In addition, the minority assays discussed here might differ in terms of their technical validation and test accuracy. We therefore assume that some studies will be more meaningful than others. This could potentially confound combined study data; consequently, reviews should be interpreted cautiously when there is the potential for differing test accuracies between studies.
In conclusion, this review highlights that AS-PCR is a useful tool for investigations of prevalence of drug resistance mutations. However, the increased detection of drug resistance using AS-PCR as compared with standard genotyping is not uniform for all mutations.
